Horse, turkey and guinea pig red blood cells

The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price contract to Lampire Biological Labs, Inc. for a period of 12 (twelve) months plus four (4) twelve (12)-month option years for turkey, guinea pig and horse red blood cells.  This procurement will satisfy the Agency’s requirements because Lampire Biological Labs, Inc. has supplied red blood cells to CDC for five (five) years for use in the hemagglutination inhibition (HI) asssays for antigenic characterization of influenza viruses.   A notable source of variation iin the HI assays stems from the source of red blood cells.  In order to liimit this source of variability and maintain consistency in antigenic characterization of influenza strains, the  Influenza Division  must maintain the same source of red blood cells.  This contract action is for supplies for which the Government intends to solicit and negotiate with only one source under the authority of FAR 6.302-1 and 41 U.S.C. 3304(a)(1).  Interested persons may identify their interest and capability to respond to the requirement or submit proposals.

This notice of intent is not a request for competitive quotations; however, all quotations/responses received within fifteen (15) days of the issuance of this notice will be considered by the government.  A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.  Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.  Any quotation/response should be emailed to contract specialist at tesslinger@cdc.gov by COB March 29, 2023.